AbbVie

Key TakeawaysAbbVie gains access to a novel BBB-crossing technology enhancing CNS drug delivery. Integration of ALIA-1758 could position AbbVie as a leader in...

Key Takeaways • Epcoritamab combined with R-CHOP achieved a 100% overall response rate in high-risk DLBCL patients. • Over half of the complete responders in the...

Key TakeawaysTavapadon offers a novel mechanism as the first D1/D5 partial agonist for Parkinson’s. The drug demonstrated consistent safety with mostly mild to...

Key TakeawaysDiverse CLL patients seek culturally relevant support resources. Significant financial stress reported among Hispanic patients. Underrepresentation in online support group usage remains...

Key TakeawaysThe high response rates suggest epcoritamab could become a new standard for R/R follicular lymphoma. Mild CRS events indicate manageable safety concerns...

Key TakeawaysELAHERE offers a targeted therapy option, potentially improving survival outcomes for FR-positive, platinum-resistant ovarian cancer patients. The VENTANA FOLR1 assay facilitates precise...

Key TakeawaysEmraclidine's tolerability supports its continued investigation in the neuroscience pipeline. The negative trial outcome necessitates a reassessment of dosage or trial design...

Key TakeawaysVYALEV, the first FDA-approved 24-hour subcutaneous levodopa infusion therapy, promises to improve motor fluctuation management in advanced Parkinson’s patients. The Neria Guard...

Key TakeawaysBOTOX® Cosmetic becomes the first FDA-approved neurotoxin for treating moderate to severe vertical platysma bands in the neck and jawline. This approval...

Key FindingsTavapadon met the primary endpoint in the pivotal Phase 3 TEMPO-1 trial, demonstrating significant improvement in MDS-UPDRS Parts II and III combined...

Key HighlightsTelisotuzumab Vedotin (Teliso-V) is an investigational antibody-drug conjugate (ADC) aimed at treating previously treated non-squamous non-small cell lung cancer (NSCLC) patients with...

Key TakeawaysTavapadon has shown significant improvements in motor function for early-stage Parkinson's disease patients, achieving both primary and secondary endpoints in AbbVie's Phase...

Key TakeawaysJUVÉDERM® VOLUMA® XC, the first and only FDA-approved hyaluronic acid filler for temple hollowing, is now available across the U.S. Over 85%...

Key TakeawaysThe Measure Up 1 and Measure Up 2 Phase 3 studies evaluated upadacitinib's efficacy in head and neck atopic dermatitis. Patients receiving...

Key TakeawaysElahere (mirvetuximab soravtansine) is designed to treat adults with FR-alpha–positive epithelial ovarian, fallopian tube, and primary peritoneal cancers that are resistant to...